Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07482176 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, sponsored by Adverum Biotechnologies.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
- 2
- Study locations
NCT07482176: Recruiting Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, sponsored by Adverum Biotechnologies.
NCT07482176 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD that is actively recruiting participants, run by Adverum Biotechnologies. The registered enrollment target is 284 participants, above the 177-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (60% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07482176, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, is actively recruiting participants, sponsored by Adverum Biotechnologies.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.
Primary Outcome
BCVA will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.
Conditions Studied
Interventions
- GENETIC Ixo-vec
- DRUG Aflibercept
Study Locations (2)
Texas
- Adverum Clinical Site 231 - The Woodlands
Virginia
- Adverum Clinical Site 199 - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2031-10-20 |
| Phase | Phase 3 |
What NCT07482176 shows while recruiting
NCT07482176 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, above the 177-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (60% higher).
The record links to 2 conditions, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which Ixo-vec is the first listed.
NCT07482176 reports a single indexed study location in Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07482176 about?
NCT07482176 is a clinical study titled "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)". This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection o...
What is the current status of trial NCT07482176?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2026-03-16. Estimated completion is 2031-10-20.
What conditions does trial NCT07482176 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD), Wet AMD.
What interventions are being tested in trial NCT07482176?
The interventions under investigation include: Ixo-vec (GENETIC), Aflibercept (DRUG).
Who is sponsoring clinical trial NCT07482176?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07482176 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07482176's enrollment target sits among peer trials
284 2nd of 9 higher than 7 of 9 other Neovascular Age-related Macular Degeneration (nAMD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration (nAMD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
COMPLETED · Phase 3
-
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
COMPLETED · Phase 3
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- NCT07105098 · 284 participants · Phase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI